Natalie Halladin

795 total citations
19 papers, 622 citations indexed

About

Natalie Halladin is a scholar working on Endocrinology, Diabetes and Metabolism, Molecular Biology and Pathology and Forensic Medicine. According to data from OpenAlex, Natalie Halladin has authored 19 papers receiving a total of 622 indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Endocrinology, Diabetes and Metabolism, 10 papers in Molecular Biology and 6 papers in Pathology and Forensic Medicine. Recurrent topics in Natalie Halladin's work include Diabetes Treatment and Management (10 papers), Metabolism, Diabetes, and Cancer (9 papers) and Diabetes Management and Research (8 papers). Natalie Halladin is often cited by papers focused on Diabetes Treatment and Management (10 papers), Metabolism, Diabetes, and Cancer (9 papers) and Diabetes Management and Research (8 papers). Natalie Halladin collaborates with scholars based in Denmark, United States and Spain. Natalie Halladin's co-authors include Ismail Gögenür, Jacob Rosenberg, Liana K. Billings, Randi Grøn, Esteban Jódar, Nikolaοs Tentolouris, Stewart B. Harris, D. Gouet, Helena W. Rodbard and Ankur Doshi and has published in prestigious journals such as Diabetes Care, Diabetes and Cochrane Database of Systematic Reviews.

In The Last Decade

Natalie Halladin

19 papers receiving 605 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Natalie Halladin Denmark 11 321 243 118 76 74 19 622
Brunella Licchelli Italy 18 412 1.3× 177 0.7× 115 1.0× 28 0.4× 48 0.6× 39 780
Ragnar Henningsson Sweden 17 207 0.6× 323 1.3× 401 3.4× 41 0.5× 81 1.1× 26 769
Howard Baldwin United States 7 350 1.1× 86 0.4× 72 0.6× 20 0.3× 25 0.3× 8 574
Christina D. Tulbert United States 11 82 0.3× 119 0.5× 55 0.5× 108 1.4× 25 0.3× 11 537
Phillippa J. Miranda United States 4 250 0.8× 133 0.5× 42 0.4× 17 0.2× 16 0.2× 4 592
Donald Newgreen United Kingdom 21 91 0.3× 408 1.7× 99 0.8× 136 1.8× 140 1.9× 42 1.4k
Amélie Paquette Canada 12 82 0.3× 80 0.3× 39 0.3× 43 0.6× 38 0.5× 16 663
Chih‐Wei Wu Taiwan 14 78 0.2× 138 0.6× 45 0.4× 17 0.2× 22 0.3× 50 646
Farzad Ebrahimi Iran 11 72 0.2× 112 0.5× 78 0.7× 26 0.3× 13 0.2× 33 481
Xing Tan China 14 37 0.1× 132 0.5× 51 0.4× 67 0.9× 60 0.8× 34 440

Countries citing papers authored by Natalie Halladin

Since Specialization
Citations

This map shows the geographic impact of Natalie Halladin's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Natalie Halladin with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Natalie Halladin more than expected).

Fields of papers citing papers by Natalie Halladin

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Natalie Halladin. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Natalie Halladin. The network helps show where Natalie Halladin may publish in the future.

Co-authorship network of co-authors of Natalie Halladin

This figure shows the co-authorship network connecting the top 25 collaborators of Natalie Halladin. A scholar is included among the top collaborators of Natalie Halladin based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Natalie Halladin. Natalie Halladin is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

19 of 19 papers shown
1.
Billings, Liana K., Yüksel Altuntaş, Randi Grøn, et al.. (2020). The Benefit of Insulin Degludec/Liraglutide (IDegLira) Compared With Basal-Bolus Insulin Therapy is Consistent Across Participant Subgroups With Type 2 Diabetes in the DUAL VII Randomized Trial. Journal of Diabetes Science and Technology. 15(3). 636–645. 5 indexed citations
2.
3.
Aroda, Vanita R., Guillermo González-Gálvez, Randi Grøn, et al.. (2019). Durability of insulin degludec plus liraglutide versus insulin glargine U100 as initial injectable therapy in type 2 diabetes (DUAL VIII): a multicentre, open-label, phase 3b, randomised controlled trial. The Lancet Diabetes & Endocrinology. 7(8). 596–605. 49 indexed citations
4.
Philis‐Tsimikas, Athena, Liana K. Billings, Robert S. Busch, et al.. (2019). Superior efficacy of insulin degludec/liraglutide versus insulin glargine U100 as add‐on to sodium‐glucose co‐transporter‐2 inhibitor therapy: A randomized clinical trial in people with uncontrolled type 2 diabetes. Diabetes Obesity and Metabolism. 21(6). 1399–1408. 54 indexed citations
5.
6.
7.
Lingvay, Ildiko, Yehuda Handelsman, Sultan Linjawi, et al.. (2018). Efficacy and Safety of Ideglira in Older Patients with Type 2 Diabetes. Endocrine Practice. 25(2). 144–155. 10 indexed citations
8.
Billings, Liana K., David C. Klonoff, Nikolaοs Tentolouris, et al.. (2018). Efficacy of IDegLira vs. Basal-Bolus Therapy in Subjects with Type 2 Diabetes in DUAL VII by Baseline Characteristics. Diabetes. 67(Supplement_1). 3 indexed citations
9.
Ekeloef, Sarah, Natalie Halladin, Siv Fonnes, et al.. (2017). Effect of Intracoronary and Intravenous Melatonin on Myocardial Salvage Index in Patients with ST-Elevation Myocardial Infarction: a Randomized Placebo Controlled Trial. Journal of Cardiovascular Translational Research. 10(5-6). 470–479. 43 indexed citations
10.
Harris, Stewart B., Győző Kocsis, Rudolf Prager, et al.. (2017). Safety and Efficacy of Insulin Degludec/Liraglutide (IDegLira) Titrated Once Weekly (1W) versus Twice Weekly (2W) in Patients with T2D Uncontrolled on Oral Antidiabetic Drugs: DUAL VI Study. Canadian Journal of Diabetes. 41(5). S58–S58. 2 indexed citations
11.
Harris, Stewart B., Győző Kocsis, Rudolf Prager, et al.. (2017). Safety and efficacy of IDegLira titrated once weekly versus twice weekly in patients with type 2 diabetes uncontrolled on oral antidiabetic drugs: DUAL VI randomized clinical trial. Diabetes Obesity and Metabolism. 19(6). 858–865. 57 indexed citations
12.
Halladin, Natalie, Svend Eggert Jensen, Jens Aarøe, et al.. (2015). Melatonin does not affect oxidative/inflammatory biomarkers in a closed-chest porcine model of acute myocardial infarction.. PubMed. 28(4). 483–8. 10 indexed citations
13.
Halladin, Natalie. (2015). Oxidative and inflammatory biomarkers of ischemia and reperfusion injuries.. PubMed. 62(4). B5054–B5054. 80 indexed citations
14.
Hansen, M., Natalie Halladin, Jacob Rosenberg, Ismail Gögenür, & Ann Merete Møller. (2015). Melatonin for pre- and postoperative anxiety in adults. Cochrane Database of Systematic Reviews. CD009861–CD009861. 71 indexed citations
15.
Halladin, Natalie, Svend Eggert Jensen, Henrik Steen Hansen, et al.. (2014). Intracoronary and systemic melatonin to patients with acute myocardial infarction: protocol for the IMPACT trial.. PubMed. 61(2). A4773–A4773. 18 indexed citations
16.
17.
Halladin, Natalie, Svend Eggert Jensen, Tomás Zaremba, et al.. (2014). Effects of intracoronary melatonin on ischemia–reperfusion injury in ST-elevation myocardial infarction. Heart and Vessels. 31(1). 88–95. 23 indexed citations
18.
Halladin, Natalie, Mahdi Alamili, Klaus Bendtzen, et al.. (2014). Lower limb ischaemia and reperfusion injury in healthy volunteers measured by oxidative and inflammatory biomarkers. Perfusion. 30(1). 64–70. 18 indexed citations
19.
Halladin, Natalie, et al.. (2012). [Closed-chest porcine model is superior in intervention studies of ischaemia reperfusion injury].. PubMed. 174(26). 1807–10. 5 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Brunella Licchelli Breakdown of academic impact, for papers by Ragnar Henningsson Breakdown of academic impact, for papers by Howard Baldwin Breakdown of academic impact, for papers by Christina D. Tulbert Breakdown of academic impact, for papers by Phillippa J. Miranda Breakdown of academic impact, for papers by Donald Newgreen Breakdown of academic impact, for papers by Amélie Paquette Breakdown of academic impact, for papers by Chih‐Wei Wu Breakdown of academic impact, for papers by Farzad Ebrahimi Breakdown of academic impact, for papers by Xing Tan
Rankless by CCL
2026